Drugs / IBI355
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06484855 | Jul 2024 → Jun 2025 | Sjogren syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06416787 | May 2024 → Feb 2025 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06110338 | Oct 2023 → Sep 2024 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-14 | Sperotx | Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody sperotx.com ↗ |
| 2026-07-14 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06416787 ↗ |
| Route | Intravenous | “IBI355 iv. once.” NCT06110338 ↗ |